journal article·2019-12-04Open access

The interaction between self – assembling peptides and emodin and the controlled release of emodin from in-situ hydrogel

Weipeng Wei, Cui Meng, Yuhe Wang, Yongsheng Huang, Wenbin Du, Hongfang Li, Yanfei Liu, Hong Song, Fushan Tang

Abstract

Ion-complementary self-assembling peptides have potential in delivering hydrophobic drugs. This study involved two self-assembling peptides, RADA16-I and RVDV16-I, of which RVDV16-I was a novel self-assembling peptide with different hydrophobic side chains designed from RADA16-I. The purpose of this study was to observe the interaction between different self-assembling peptides and emodin through fluorescence spectrophotometry, CD, SEM and AFM; to construct a preliminary suspension in-situ hydrogel delivery system for emodin with the self-assembling peptides; and to investigate the drug-loading and drug-releasing properties of the self-assembling peptides on emodin. The results showed that both peptides can interact with emodin and the interaction was dominated by hydrophobic interaction. The aqueous solutions of both self-assembling peptides can form relatively stable suspensions with emodin under mechanical stirring, and the suspension can form in-situ hydrogel under physiological condition. In vitro release of emodin from the hydrogels showed a manner of sustained release to some extent. Cell viability studies showed inherent proliferation inhibiting effects of emodin on tumor cells was maintained or enhanced through the in-situ hydrogels. The self-assembling peptides RADA16-I and RVDV16-I had showed promising drug-loading and drug-releasing performance for hydrophobic drugs. It is reasonable to exploit self-assembling peptides as drug carriers for their great potential to improve delivery of hydrophobic drugs.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Supramolecular Self-Assembly in Materials · RNA Interference and Gene Delivery · Glycosylation and Glycoproteins Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Clinical Pharmacy, School of Pharmacy, Zunyi Medical University

The Key Laboratory of Clinical Pharmacy in Zunyi City

Pharmacy Department, Affiliated Hospital of Zunyi Medical University

Peking Union Medical College, Chinese Academy of Medical Sciences, Institute of Basic Medical Sciences

State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences

Key Laboratory of Cell Engineering of Guizhou Province, Affiliated Hospital of Zunyi Medical University

College of Basic Medicine, Zunyi Medical University

Funding

the National Natural Science Foundation of China · Guizhou Provincial Science and Technology Foundation · Project of Special Funds for Science and Technology Cooperation in Guizhou Provinces and Zunyi City · Education Department of Guizhou Province · Collaborative Innovation Center of Guizhou Traditional Chinese Medicine and Ethnic medicine · National Key Research and Development Program of China · National Natural Science Foundation of China

References (56)

Show source-provided references
1. 10.1016/j.jddst.2015.10.01910.1016/j.jddst.2015.10.019 ↗
2. 10.1016/j.canlet.2013.08.02310.1016/j.canlet.2013.08.023 ↗
3. 10.1016/j.jep.2016.04.05810.1016/j.jep.2016.04.058 ↗
4. 10.1016/j.ejps.2016.12.01210.1016/j.ejps.2016.12.012 ↗
5. 10.2147/OTT.S13821710.2147/OTT.S138217 ↗
6. 10.1158/1535-7163.MCT-15-098710.1158/1535-7163.MCT-15-0987 ↗
7. 10.1016/j.biocel.2018.01.01410.1016/j.biocel.2018.01.014 ↗
8. Xie QC, Yang YP. Anti-proliferative of physcion 8-O-β-glucopyranoside isolated from Rumex japonicus Houtt. on A549 cell lines via inducing apoptosis and cell cycle arrest. BMC Complem Alter. 2014;14:1–10.
9. 10.3892/or.2017.542810.3892/or.2017.5428 ↗
10. 10.1371/journal.pone.014478110.1371/journal.pone.0144781 ↗
11. 10.1016/j.biopha.2017.03.04610.1016/j.biopha.2017.03.046 ↗
12. 10.1016/j.bbrc.2009.10.15310.1016/j.bbrc.2009.10.153 ↗
13. 10.3892/or.2015.374410.3892/or.2015.3744 ↗
14. 10.1177/153473541666478410.1177/1534735416664784 ↗
15. 10.1016/0922-4106(94)90221-610.1016/0922-4106(94)90221-6 ↗
16. Li BJ, Liu TB, Wang WF, et al. Effect of a novel emodin derivative on chronic myelogenous leukemia K562 cells and imatinib-resistant K562/G01 cells. J Exp Hematol. 2016;24:1–7.
17. Dong H, Wu G, Xu H, et al. N-acetylaminogalactosyl-decorated biodegradable PLGA-TPGS copolymer nanoparticles containing emodin for the active targeting therapy of liver cancer. Artif Cells Nanomed Biotechnol. 2018;1:1–13.
18. 10.1007/s11095-016-2010-510.1007/s11095-016-2010-5 ↗
19. 10.1007/s11095-015-1781-410.1007/s11095-015-1781-4 ↗
20. 10.1016/j.ijpharm.2016.04.02110.1016/j.ijpharm.2016.04.021 ↗
21. 10.3390/ijms1403649910.3390/ijms14036499 ↗
22. 10.1016/j.eurpolymj.2015.10.03310.1016/j.eurpolymj.2015.10.033 ↗
23. 10.1038/srep3762610.1038/srep37626 ↗
24. 10.1016/j.matlet.2016.12.12710.1016/j.matlet.2016.12.127 ↗
25. 10.1093/rb/rbw03410.1093/rb/rbw034 ↗
26. 10.1021/acs.biomac.7b0078710.1021/acs.biomac.7b00787 ↗
27. 10.1016/j.actbio.2016.09.03310.1016/j.actbio.2016.09.033 ↗
28. 10.1016/j.msec.2016.01.05710.1016/j.msec.2016.01.057 ↗
29. 10.3390/pathogens304079110.3390/pathogens3040791 ↗
30. 10.1186/s12896-018-0422-510.1186/s12896-018-0422-5 ↗
31. 10.1016/j.addr.2016.08.00610.1016/j.addr.2016.08.006 ↗
32. 10.1016/j.addr.2016.08.00510.1016/j.addr.2016.08.005 ↗
33. 10.1016/j.addr.2016.06.00610.1016/j.addr.2016.06.006 ↗
34. Koutsopoulos S. Self-assembling peptides in biomedicine and bioengineering: tissue engineering, regenerative medicine, drug delivery, and biotechnology. Peptide Appl Biomed Biotechnol Bioeng. 2018;15:387–408.
35. 10.4155/tde.11.7410.4155/tde.11.74 ↗
36. 10.1016/j.addr.2016.06.01310.1016/j.addr.2016.06.013 ↗
37. 10.1073/pnas.090002610610.1073/pnas.0900026106 ↗
38. 10.2147/IJN.S2403810.2147/IJN.S24038 ↗
39. 10.2147/IJN.S10470710.2147/IJN.S104707 ↗
40. Hu C, Huang P. Recent research progress in the determination of solid solubility. J Pharm Anal. 2010;22(4):761–766.
41. Yuan L, Zhong S, Zhou R, et al. Determination of the equilibrium solubility and apparent oil-water partition coefficient of cantharidin by HPLC. Chin J New Drugs. 2017;26(10):1185–1188.
42. Li F, Ding Z, Cao Q. Determination of dissociation constants of five rhubarb anthraquinone derivatives. Chin J Tradit Chin Med. 2007;32(2):166–168.
43. Bin Y. Study of emodin liposome. Dissertation. 2009.
44. National Pharmacopoeia Commission. Pharmacopoeia of the People’s Republic of China. Beijing (China): China Medical Science and Technology Press; 2015.
45. 10.1088/1748-605X/aab2fd10.1088/1748-605X/aab2fd ↗
46. 10.1088/1748-605X/12/1/01500710.1088/1748-605X/12/1/015007 ↗
47. 10.1016/j.colsurfb.2016.05.03010.1016/j.colsurfb.2016.05.030 ↗
48. 10.2174/138161282166615090110482110.2174/1381612821666150901104821 ↗
49. 10.1016/j.chemphys.2013.02.02810.1016/j.chemphys.2013.02.028 ↗
50. 10.1021/acs.jproteome.8b0002910.1021/acs.jproteome.8b00029 ↗
51. 10.1002/jps.2197810.1002/jps.21978 ↗
52. 10.1016/j.jddst.2017.09.01210.1016/j.jddst.2017.09.012 ↗
53. 10.1016/j.jconrel.2013.08.00610.1016/j.jconrel.2013.08.006 ↗
54. 10.1016/j.jcis.2016.09.00310.1016/j.jcis.2016.09.003 ↗
55. 10.1016/j.nano.2016.08.00710.1016/j.nano.2016.08.007 ↗
56. Pawar SS, Dahifale BR, Nagargoje SP, et al. Nanosuspension technologies for delivery of drugs. Nanosci Nanotech Res. 2017;4:59–66.